摘要
心脑血管疾病是一种严重威胁人类健康的常见疾病,居各种死因的首位。其中,胆固醇尤其是低密度脂蛋白胆固醇(LDL-C)与其发病息息相关。目前指南推荐控制LDL-C的首选药物是他汀类药物,但其服用后可出现多种不良反应。人前蛋白转化酶枯草溶菌素9(PCSK9)近年来被发现与LDL-C有密切的相关性,目前已有大量的研究可以证明PCSK9抑制剂可降低血LDL-C水平,甚至有机会应用于降压治疗。本文将系统综述PCSK9抑制剂在高脂血症及高血压中的研究现状。
Cardiovascular and cerebrovascular disease(CVD)is a serious threat to human health.Among them,cholesterol,especially low-density lipoprotein cholesterol(LDL-C),is closely related to the pathogenesis.The current guidelines recommend statins as the first choice for LDL-C control,Howerer,some data showed that after taking can appear a variety of adverse reactions.In recent years,human proprotein invertase subtilis 9(PCSK9)has been found to have a close correlation with LDL-C.At present,a large number of studies have proved that PCSK9 inhibitors can reduce the level of LDL-C in blood,and even have the opportunity to be applied in the antihypertensive therapy.In this paper,the research status of PCSK9 inhibitors in hyperlipidemia and hypertension was systematically reviewed.
作者
陈璐
李婧
CHEN Lu;LI Jing(Wuhan University of Science and Technology Clinical College, Hubei Province, Wuhan 430064, China)
出处
《中国医药导报》
CAS
2019年第12期42-45,共4页
China Medical Herald
基金
湖北省自然科学基金资助项目(2018CFC817)
